NanoString Technologies, the Seattle-based maker of genetic analysis instruments, has collected $2.5 million in new financing, according to a regulatory filing. NanoString’s financing, which could be worth as much as $14 million over time, comes in the form of debt that be converted later into equity holdings, as well as warrants to buy shares in the future at a certain price, according to the filing. NanoString last raised $30 million in an equity financing two years ago.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
